These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 7609036)

  • 1. Vaccination with recombinant vaccinia viruses expressing ICP27 induces protective immunity against herpes simplex virus through CD4+ Th1+ T cells.
    Manickan E; Francotte M; Kuklin N; Dewerchin M; Molitor C; Gheysen D; Slaoui M; Rouse BT
    J Virol; 1995 Aug; 69(8):4711-6. PubMed ID: 7609036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protective immunity against herpes simplex virus (HSV) type 1 following oral administration of recombinant Salmonella typhimurium vaccine strains expressing HSV antigens.
    Karem KL; Bowen J; Kuklin N; Rouse BT
    J Gen Virol; 1997 Feb; 78 ( Pt 2)():427-34. PubMed ID: 9018066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of different forms of herpes simplex replication-defective mutant viruses as vaccines in a mouse model of HSV-2 genital infection.
    Da Costa XJ; Morrison LA; Knipe DM
    Virology; 2001 Sep; 288(2):256-63. PubMed ID: 11601897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of HSV-specific CD4+ Th1 responses and CD8+ cytotoxic T lymphocytes with antiviral activity by vaccination with the HSV-2 mutant ICP10DeltaPK.
    Gyotoku T; Ono F; Aurelian L
    Vaccine; 2002 Jun; 20(21-22):2796-807. PubMed ID: 12034107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo modulation of vaccine-induced immune responses toward a Th1 phenotype increases potency and vaccine effectiveness in a herpes simplex virus type 2 mouse model.
    Sin JI; Kim JJ; Boyer JD; Ciccarelli RB; Higgins TJ; Weiner DB
    J Virol; 1999 Jan; 73(1):501-9. PubMed ID: 9847356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of adjuvant efficacy of herpes simplex virus type 1 recombinant viruses expressing TH1 and TH2 cytokine genes.
    Osorio Y; Ghiasi H
    J Virol; 2003 May; 77(10):5774-83. PubMed ID: 12719570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune responses to herpes simplex virus in guinea pigs (footpad model) and mice immunized with vaccinia virus recombinants containing herpes simplex virus glycoprotein D.
    Aurelian L; Smith CC; Wachsman M; Paoletti E
    Rev Infect Dis; 1991; 13 Suppl 11():S924-34. PubMed ID: 1664130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Herpes simplex virus type 1-specific cytotoxic T lymphocytes recognize immediate-early protein ICP27.
    Banks TA; Allen EM; Dasgupta S; Sandri-Goldin R; Rouse BT
    J Virol; 1991 Jun; 65(6):3185-91. PubMed ID: 1709698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a glycoprotein D-expressing dominant-negative and replication-defective herpes simplex virus 2 (HSV-2) recombinant viral vaccine against HSV-2 infection in mice.
    Akhrameyeva NV; Zhang P; Sugiyama N; Behar SM; Yao F
    J Virol; 2011 May; 85(10):5036-47. PubMed ID: 21389121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA vaccines encoding interleukin-8 and RANTES enhance antigen-specific Th1-type CD4(+) T-cell-mediated protective immunity against herpes simplex virus type 2 in vivo.
    Sin J; Kim JJ; Pachuk C; Satishchandran C; Weiner DB
    J Virol; 2000 Dec; 74(23):11173-80. PubMed ID: 11070014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel Role for Interleukin-17 in Enhancing Type 1 Helper T Cell Immunity in the Female Genital Tract following Mucosal Herpes Simplex Virus 2 Vaccination.
    Bagri P; Anipindi VC; Nguyen PV; Vitali D; Stämpfli MR; Kaushic C
    J Virol; 2017 Dec; 91(23):. PubMed ID: 28956763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prophylactic herpes simplex virus type 2 vaccine adjuvanted with a universal CD4 T cell helper peptide induces long-term protective immunity against lethal challenge in mice.
    Li X; Zhang S; Lei J; Zhu Y; Zhou X; Xiao J; Xiang T
    Int Immunopharmacol; 2018 Aug; 61():100-108. PubMed ID: 29857239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monophosphoryl lipid A and QS21 increase CD8 T lymphocyte cytotoxicity to herpes simplex virus-2 infected cell proteins 4 and 27 through IFN-gamma and IL-12 production.
    Mikloska Z; Rückholdt M; Ghadiminejad I; Dunckley H; Denis M; Cunningham AL
    J Immunol; 2000 May; 164(10):5167-76. PubMed ID: 10799875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of murine cytomegalovirus (MCMV) replication with a DNA vaccine encoding MCMV M84 (a homolog of human cytomegalovirus pp65).
    Morello CS; Cranmer LD; Spector DH
    J Virol; 2000 Apr; 74(8):3696-708. PubMed ID: 10729145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunization with a single major histocompatibility complex class I-restricted cytotoxic T-lymphocyte recognition epitope of herpes simplex virus type 2 confers protective immunity.
    Blaney JE; Nobusawa E; Brehm MA; Bonneau RH; Mylin LM; Fu TM; Kawaoka Y; Tevethia SS
    J Virol; 1998 Dec; 72(12):9567-74. PubMed ID: 9811690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccination with recombinant modified vaccinia virus Ankara prevents the onset of intestinal allergy in mice.
    Bohnen C; Wangorsch A; Schülke S; Nakajima-Adachi H; Hachimura S; Burggraf M; Süzer Y; Schwantes A; Sutter G; Waibler Z; Reese G; Toda M; Scheurer S; Vieths S
    Allergy; 2013 Aug; 68(8):1021-8. PubMed ID: 23909913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccination with the immediate-early protein ICP47 of herpes simplex virus-type 1 (HSV-1) induces virus-specific lymphoproliferation, but fails to protect against lethal challenge.
    Banks TA; Jenkins FJ; Kanangat S; Nair S; Dasgupta S; Foster CM; Rouse BT
    Virology; 1994 Apr; 200(1):236-45. PubMed ID: 8128625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of cellular responses by plasmid CD40L: CD40L plasmid vectors enhance antigen-specific helper T cell type 1 CD4+ T cell-mediated protective immunity against herpes simplex virus type 2 in vivo.
    Sin JI; Kim JJ; Zhang D; Weiner DB
    Hum Gene Ther; 2001 Jun; 12(9):1091-102. PubMed ID: 11399230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity of herpes simplex virus type 1 mutants containing deletions in one or more alpha-genes: ICP4, ICP27, ICP22, and ICP0.
    Brehm M; Samaniego LA; Bonneau RH; DeLuca NA; Tevethia SS
    Virology; 1999 Apr; 256(2):258-69. PubMed ID: 10191191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of protective immunity against herpes simplex virus with DNA encoding the immediate early protein ICP 27.
    Manickan E; Yu Z; Rouse RJ; Wire WS; Rouse BT
    Viral Immunol; 1995; 8(2):53-61. PubMed ID: 8825290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.